226 related articles for article (PubMed ID: 7644079)
21. Valdecoxib for treatment of a single, acute, moderate to severe migraine headache.
Kudrow D; Thomas HM; Ruoff G; Ishkanian G; Sands G; Le VH; Brown MT
Headache; 2005 Oct; 45(9):1151-62. PubMed ID: 16178945
[TBL] [Abstract][Full Text] [Related]
22. Treatment of menstruation-associated migraine headache with subcutaneous sumatriptan.
Solbach MP; Waymer RS
Obstet Gynecol; 1993 Nov; 82(5):769-72. PubMed ID: 8414324
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of sumatriptan 50 mg in patients not responding to standard care, in the treatment of mild to moderate migraine. The Sumatriptan 50 mg Italian Study Group.
Pini LA; Fabbri L; Cavazzuti L
Int J Clin Pharmacol Res; 1999; 19(2):57-64. PubMed ID: 10669900
[TBL] [Abstract][Full Text] [Related]
24. Oral sumatriptan for migraine in children and adolescents: a randomized, multicenter, placebo-controlled, parallel group study.
Fujita M; Sato K; Nishioka H; Sakai F
Cephalalgia; 2014 Apr; 34(5):365-75. PubMed ID: 24163282
[TBL] [Abstract][Full Text] [Related]
25. [Sumatriptan treatment of migraine in general practice. A randomized, double-blind, placebo-controlled cross-over study].
Russell MB; Holm-Thomsen OE; Nielsen MR; Cleal A; Pilgrim AJ; Olesen J
Ugeskr Laeger; 1995 Apr; 157(16):2320-3. PubMed ID: 7652970
[TBL] [Abstract][Full Text] [Related]
26. Patient preference for oral sumatriptan 25 mg, 50 mg, or 100 mg in the acute treatment of migraine: a double-blind, randomized, crossover study. Sumatriptan Tablets S2CM11 Study Group.
Salonen R; Ashford EA; Gibbs M; Hassani H
Int J Clin Pract Suppl; 1999 Aug; 105():16-24. PubMed ID: 10692718
[TBL] [Abstract][Full Text] [Related]
27. Transdermal sumatriptan for acute treatment of migraineurs with baseline nausea.
Schulman EA
Headache; 2012 Feb; 52(2):204-12. PubMed ID: 22229837
[TBL] [Abstract][Full Text] [Related]
28. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study).
Mathew NT; Finlayson G; Smith TR; Cady RK; Adelman J; Mao L; Wright P; Greenberg SJ;
Headache; 2007 Feb; 47(2):189-98. PubMed ID: 17300358
[TBL] [Abstract][Full Text] [Related]
29. Long-term tolerability of sumatriptan nasal spray in adolescent patients with migraine.
Natarajan S; Jabbour JT; Webster CJ; Richardson MS
Headache; 2004; 44(10):969-77. PubMed ID: 15546259
[TBL] [Abstract][Full Text] [Related]
30. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine.
Aurora SK; Rozen TD; Kori SH; Shrewsbury SB
Headache; 2009 Jun; 49(6):826-37. PubMed ID: 19545249
[TBL] [Abstract][Full Text] [Related]
31. Comparison of rizatriptan 5 mg and 10 mg tablets and sumatriptan 25 mg and 50 mg tablets.
Kolodny A; Polis A; Battisti WP; Johnson-Pratt L; Skobieranda F;
Cephalalgia; 2004 Jul; 24(7):540-6. PubMed ID: 15196296
[TBL] [Abstract][Full Text] [Related]
32. [Evaluation of efficacy and tolerance sumatriptan at a dose of 50 mg in treatment of migraine attack].
Prusiński A; Król F
Pol Merkur Lekarski; 1998 Mar; 4(21):158-61. PubMed ID: 9640070
[TBL] [Abstract][Full Text] [Related]
33. Pain-free results with sumatriptan taken at the first sign of migraine pain: 2 randomized, double-blind, placebo-controlled studies.
Winner P; Mannix LK; Putnam DG; McNeal S; Kwong J; O'Quinn S; Richardson MS
Mayo Clin Proc; 2003 Oct; 78(10):1214-22. PubMed ID: 14531480
[TBL] [Abstract][Full Text] [Related]
34. Almotriptan improves response rates when treatment is within 1 hour of migraine onset.
Dowson AJ; Massiou H; Lainez JM; Cabarrocas X
Headache; 2004 Apr; 44(4):318-22. PubMed ID: 15109355
[TBL] [Abstract][Full Text] [Related]
35. Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: A randomised, placebo-controlled study.
Djupesland PG; Docekal P;
Cephalalgia; 2010 Aug; 30(8):933-42. PubMed ID: 20656704
[TBL] [Abstract][Full Text] [Related]
36. Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies.
Ryan R; Elkind A; Baker CC; Mullican W; DeBussey S; Asgharnejad M
Neurology; 1997 Nov; 49(5):1225-30. PubMed ID: 9371898
[TBL] [Abstract][Full Text] [Related]
37. DFN-02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double-Blind, Placebo-Controlled Study.
Lipton RB; Munjal S; Brand-Schieber E; Rapoport AM
Headache; 2018 May; 58(5):676-687. PubMed ID: 29878341
[TBL] [Abstract][Full Text] [Related]
38. Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered
Silberstein S; Winner PK; McAllister PJ; Tepper SJ; Halker R; Mahmoud RA; Siffert J
Headache; 2017 Jun; 57(6):862-876. PubMed ID: 28497569
[TBL] [Abstract][Full Text] [Related]
39. Subcutaneous sumatriptan in acute treatment of migraine: a multicentre New Zealand trial.
Thomson AN; Arthur GP; Bergin PS; Pollock M; Parkin PJ; Flanagan M; Samson SA
N Z Med J; 1993 May; 106(955):171-3. PubMed ID: 8389026
[TBL] [Abstract][Full Text] [Related]
40. A sumatriptan iontophoretic transdermal system for the acute treatment of migraine.
Goldstein J; Smith TR; Pugach N; Griesser J; Sebree T; Pierce M
Headache; 2012 Oct; 52(9):1402-10. PubMed ID: 22694484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
